Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML

Clinical trial NCT04402723 · TERMINATED

Trial details

NCT number: NCT04402723
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Acute Myeloid Leukemia (AML)

Start date: 2018-11-06
Primary completion: 2022-02-09
Enrollment: 8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.